Aijaz Ahmed, MD

Articles by Aijaz Ahmed, MD

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

ByZobair Younossi, MD,Stuart C. Gordon, MD,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD,Rachel Beckerman, PhD

February 16th 2017

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

ByZobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD,Haesuk Park, PhD,Stuart C. Gordon, MD,John R. Ferguson,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD, MPH

May 3rd 2016

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

Latest Updated Articles

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C
Published: May 3rd 2016 | Updated:
Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
Published: February 16th 2017 | Updated:

Aijaz Ahmed, MD

Articles by Aijaz Ahmed, MD

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

Latest Updated Articles

Trending on AJMC

FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH

In Primary Care–Oncology Collaboration, the Baton Goes Both Ways

FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer

US, Japan Patients With Diabetes Discontinue Semaglutide After First Year

Improving Access and Care for All Patients With Atopic Dermatitis